Novel bridged indole carboxylic acid derivatives for multi-purpose pharmacological screening

Overview

This offering is a curated library of novel small organic compounds based on bridged indole carboxylic acid derivatives. The compounds are designed around an underrepresented 3,4-substitution pattern, opening access to chemical space that is less explored in conventional indole medicinal chemistry programs. The library is intended for multi-purpose pharmacological screening, enabling evaluation across a range of assays and target classes.

Indole derivatives are a well-established source of pharmacologically active molecules, with numerous approved drugs already on the market across indications such as oncology, CNS disorders, inflammation, and infectious disease. By focusing on the 3,4-substitution pattern, this library aims to generate novel scaffolds that may offer differentiated binding, selectivity, or pharmacokinetic properties compared to more common indole substitution strategies.

Technical specifications

Compound design:

• Small organic molecules built on a bridged indole carboxylic acid core
• Design strategy leverages the underrepresented 3,4-substitution pattern to expand accessible chemical space
• Library format suitable for high-throughput and target-based screening workflows

Intended applications:

• Broad pharmacological activity profiling across multiple assay systems
• Hit identification and lead generation for drug discovery programs
• Feasibility of use across diverse target classes consistent with the polypharmacology of indole scaffolds

Research context:

• Developed at Universität Greifswald, a research university with integrated clinical and laboratory capabilities
• Supported by a dedicated technology transfer office for IP, licensing, and collaboration management

Technology readiness level

The compounds have been designed and synthesized as a small library and are positioned for evaluation in pharmacological assays. The offering is at an early-stage research phase, suitable for screening partnerships, collaborative profiling, and hit-to-lead follow-up. Further validation, including target-specific assay data and structure-activity relationship studies, is expected as part of collaborative screening campaigns.